Lexaria Bioscience Corp. (NASDAQ: LEXX)
$3.05
+0.0800 ( +2.69% ) 32.8K
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Market Data
Open
$3.05
Previous close
$2.97
Volume
32.8K
Market cap
$46.13M
Day range
$2.80 - $2.96
52 week range
$0.73 - $6.85
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 68 | Jul 12, 2024 |
4 | Insider transactions | 1 | May 15, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
4 | Insider transactions | 1 | May 10, 2024 |
8-k | 8K-related | 17 | Apr 30, 2024 |